## ALL: The Allstate Corporation - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.24 indicates fundamental undervaluation. Quality metrics strong (ROE 34%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-6.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($194.97)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Allstate (NYSE: ALL) CEO Thomas J. Wilson reports open-market stock sales**
- Source: Stock Titan | 20251204T040907 | Somewhat-Bearish | Relevance: 100%
- Allstate Corporation's Chairman, President, and CEO Thomas J. Wilson reported open-market sales of company stock on December 1, 2025. He sold a total of 16,807 shares in two transactions, carried out under a Rule 10b5-1 trading plan adopted in June 2025. Following these sales, Wilson directly holds 144,812.491 shares and has additional indirect ownership through various trusts and plans.

**2. Allstate Car Insurance Review (2025)**
- Source: Insurify | 20251204T190758 | Neutral | Relevance: 100%
- This detailed review of Allstate Car Insurance highlights its position as the fourth-largest car insurance company in the U.S. It covers customer feedback, industry ratings, comparisons with competitors, coverage options, and the claims process. While Allstate offers competitive rates and a superior financial strength rating, customer satisfaction and claims handling receive mixed reviews.

**3. AI & the Future of the Insurance Industry**
- Source: EPAM | 20251203T112822 | Somewhat-Bullish | Relevance: 74%
- This article discusses the future of AI in the insurance industry, drawing insights from a panel discussion at ITC Vegas 2025. Key challenges highlighted include legacy systems, data quality issues, and the need for effective change management. The experts emphasize the importance of clean data, strategic use cases, and addressing people/culture aspects for successful AI adoption.

**4. Korea Investment CORP Sells 58,400 Shares of Aptiv PLC $APTV**
- Source: MarketBeat | 20251203T113623 | Neutral | Relevance: 71%
- Korea Investment CORP reduced its stake in Aptiv PLC by 32.3% in the second quarter, selling 58,400 shares and now owning 122,228 shares valued at $8.34 million. Despite the institutional selling, Wall Street analysts maintain a "Moderate Buy" consensus with an average price target of $95.42. Aptiv also reported strong quarterly earnings, beating estimates with $2.17 EPS and $5.21 billion in revenue, and provided optimistic FY2025 guidance.

**5. Compare Progressive vs. Travelers: Quotes, Discounts (2025)**
- Source: Insurify | 20251204T070921 | Neutral | Relevance: 65%
- This article compares Progressive and Travelers, two of the largest U.S. car insurance companies, based on rates, discounts, coverage options, and customer satisfaction. While Progressive generally offers cheaper average rates, Travelers provides more coverage options and discounts, including new-car replacement and accident forgiveness. The comparison helps consumers decide which insurer best fits their specific needs and financial profile.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Roth Capital | $240 | $230 | +4% |
| 2025-11-11 | Keefe, Bruyette | $250 | $246 | +2% |
| 2025-11-10 | UBS | $255 | $250 | +2% |
| 2025-11-07 | Wells Fargo | $216 | $202 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Roth Capital | main | Buy |
| 2025-11-11 | Keefe, Bruyette | main | Outperform |
| 2025-11-10 | UBS | main | Buy |
| 2025-11-07 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.16M) |
| Sells | 13 ($14.04M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.7% (-0.3%)
- Blackrock Inc.: 8.5% (-1.0%)
- Price (T.Rowe) Assoc: 4.9% (-17.0%)
- State Street Corpora: 4.5% (+0.7%)
- Geode Capital Manage: 2.7% (+3.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $14M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 6 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.24 suggests fair value with growth premium. Quality metrics strong (ROE 34%). Balance sheet: strong liquidity (30938000000.0x), $3.2B free cash flow. Insider selling cluster ($14.0M in 90 days), potential headwind. Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $54.8B |
| Beta | 0.25 |
| 52W Range | $176.00 - $215.89 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.24 |
| Forward P/E | 8.4 |
| Current P/E | 7.0 |
| YoY Growth | -17.1% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 0.7% to -5.4% (-6.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.4pp (needs >4.0% for momentum thesis). AM_20 at -3.1% indicates price below own 20MA trend. Underperforming sector by 5.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.00x) but short-term weakness (below SMA20). MACD histogram bearish (-1.09), momentum weakening. RSI neutral at 41. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -5.37% (CS: 9) | Weak |
| RSI_14 | 41.1 | Neutral |
| MACD Histogram | -1.09 | Bearish |
| vs SMA20 | 0.965x | Below |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 1.004x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $202.27
- **Stop Loss:** $194.97 (3.6% risk)
- **Target:** $216.87 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 136
- **Position Value:** $27,508.72
- **Portfolio %:** 27.51%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $8.25)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.54 | $11.17 | +48.1% |
| 2025Q2 | $3.26 | $5.94 | +82.4% |
| 2025Q1 | $2.53 | $3.53 | +39.3% |
| 2024Q4 | $6.28 | $7.67 | +22.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*